✦ LIBER ✦

The FDA's poor oversight of postmarketing studies

✍ Scribed by The Lancet

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Complications of Controlling Agency

✍ Daniel Carpenter; Jacqueline Chattopadhyay; Susan Moffitt; Clayton Nall 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 612 KB

Commentary: Public Outreach by the FDA:

✍ Mark S. Frankel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Pharmacovigilance and reporting oversigh

✍ Beatrice J Edwards; Mrinal Gounder; June M McKoy; Ian Boyd; Mathew Farrugia; Ces 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 261 KB

Print news coverage of the 2010 Iowa egg

✍ Linnea I. Laestadius; Lisa P. Lagasse; Katherine Clegg Smith; Roni A. Neff 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 581 KB

The evolution of public review and overs

✍ Theodore Friedmann; Philip Noguchi; Claudia Mickelson 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Studies of the “poor sister group”

✍ Robert D. Martin 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB